TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

My Favorite Dividend King to Buy in November

The Motley Fool Logo The Motley Fool By Keith Speights
My Favorite Dividend King to Buy in November

AbbVie, a pharmaceutical company with a 53-year dividend increase streak, offers strong growth potential through successful drugs like Skyrizi and Rinvoq, and an attractive valuation with a forward P/E ratio lower than the S&P 500.

Insights
BAC   positive

First Investor Day in 14 years, recent earnings beat, and potential for optimistic outlook on consumer banking and economic trends


ABBV   positive

The article highlights AbbVie's consistent dividend growth, strong drug portfolio, promising pipeline, attractive valuation, and potential for future earnings, making it an appealing investment